The MHRA has taken decisive action to phase out animal testing by helping developers make better use of New Approach Methodologies (NAMs). By offering early reviews of non-animal data and clarifying how it will be assessed, the initiative gives developers greater confidence in developing marketing applications based on evidence generated without animal testing. The move supports the UK Government’s long-term strategy to reduce the use of animals in drug development, where complete elimination isn’t yet feasible, and to ensure medicines continue to meet rigorous safety standards. Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, explained: “A clearer regulatory route for medicines developed without animal testing will help accelerate the transition to modern, predictive science and support the government’s strategy to reduce and ultimately replace animals in research. “Advances such as AI‑driven analysis and human‑derived cell models mean some medicines no longer require animal studies to demonstrate safety and efficacy.” Phasing out animal testing in the medicine industry Phasing out the use of animals in science and product development must be supported by reliable …